uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer
BioNTech Grp Mainz, Mainz, Germany..
BioNTech Grp Mainz, Mainz, Germany..
BioNTech Grp Mainz, Mainz, Germany..
BioNTech Grp Mainz, Mainz, Germany..
Show others and affiliations
2017 (English)In: Annals of Oncology, ISSN 0923-7534, E-ISSN 1569-8041, Vol. 28, no suppl 11Article in journal, Meeting abstract (Other academic) Published
Place, publisher, year, edition, pages
Oxford University Press, 2017. Vol. 28, no suppl 11
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-348322DOI: 10.1093/annonc/mdx711.080ISI: 000424778900089OAI: oai:DiVA.org:uu-348322DiVA, id: diva2:1200701
Conference
ESMO Immuno Oncology Congress, DEC 07-10, 2017, Geneva, SWITZERLAND
Funder
EU, FP7, Seventh Framework ProgrammeAvailable from: 2018-04-24 Created: 2018-04-24 Last updated: 2018-04-24Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full text

Authority records BETA

Lindman, HenrikSjöblom, Tobias

Search in DiVA

By author/editor
Lindman, HenrikSjöblom, Tobias
By organisation
Experimental and Clinical Oncology
In the same journal
Annals of Oncology
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 26 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf